On this page

Desonide

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Desonide
Generic name
Desonide
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
14
Packages
23
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Desonide .5 mg/g 204135 View
Desonide 1 kg/kg 204135 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
37

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
210198
Application type
ANDA · Abbreviated New Drug Application
Approval date
November 20, 2019
Sponsor
CADILA
Products on application
1
Submissions recorded
1
Products approved under application 210198.
Product Trade name Form Strength Ingredient Status TE Flags
210198-001 DESONIDE CREAM DESONIDE Prescription AB RS

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 210198.
Type No. Action Status Date Review
Original application 1 Approved November 20, 2019 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260112). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260112 HUMAN PRESCRIPTION DRUG · 20250702 HUMAN PRESCRIPTION DRUG · 20250501

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Desonide cream, 0.05% and desonide ointment, 0.05% are low potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Desonide cream, 0.05% or desonide ointment, 0.05% should be applied to the affected area as a thin film two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide cream, 0.05% and desonide ointment, 0.05% should not be used with occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Desonide cream, 0.05% and desonide ointment, 0.05% are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide cream, 0.05% was approximately 1% and desonide ointment, 0.05% was approximately 6%. The adverse reactions for desonide cream, 0.05% were pruritus, pain, folliculitis, rash, peripheral edema, pustular rash, sweating, erythema, irritation, and burning. Laboratory abnormalities were found in 3% of the patients. These were hyperglycemia (2%) and liver function abnormality (1%). The adverse reactions for desonide ointment, 0.05% were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation.

Description

openFDA Drug Labeling

DESCRIPTION: Desonide Cream 0.05% and Lotion 0.05% contain desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)- a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic agents. Chemically, desonide is C 24 H 32 O 6 . It has the following structural formula: Desonide has the molecular weight of 416.51. It is a white to off white odorless powder which is soluble in methanol and practically insoluble in water. Each gram of Desonide Cream contains 0.5 mg of desonide in a base of citric acid, emulsifying wax, isopropyl palmitate, polysorbate 60, potassium sorbate, propyl gallate, propylene glycol, purified water, sodium hydroxide, sorbic acid, stearic acid, and synthetic beeswax. Each gram of Desonide Lotion contains 0.5 mg of desonide in a base of cetyl alcohol, edetate sodium, glyceryl stearate SE, light mineral oil, methylparaben, propylene glycol, propylparaben, purified water, sodium lauryl sulfate, sorbitan monostearate, and stearyl alcohol. May contain citric acid and/or sodium hydroxide for pH adjustment. deso-structure

OVERDOSAGE Topically applied desonide cream, 0.05% and desonide ointment, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Desonide cream USP, 0.05% is white to off white cream and is available as follows: NDC 72578-086-01 in tube of 15 g NDC 72578-086-02 in tube of 60 g Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Call your doctor for medical advice about side effects. You may report side effects to Viona Pharmaceuticals Inc. at 1-888-304-5011 or FDA at 1-800-FDA-1088.

Adverse event reports

Source: openFDA FAERS
4,961
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: DESONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
80425-0371-1 80425-0371 Advanced Rx of Tennessee, LLC 1 TUBE in 1 CARTON (80425-0371-1) / 60 g in 1 TUBE December 7, 2023
80425-0418-1 80425-0418 Advanced Rx of Tennessee, LLC 1 TUBE in 1 CARTON (80425-0418-1) / 60 g in 1 TUBE July 17, 2024
62332-632-15 62332-632 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-632-15) / 15 g in 1 TUBE December 8, 2022
62332-632-60 62332-632 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-632-60) / 60 g in 1 TUBE December 8, 2022
46708-632-15 46708-632 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-632-15) / 15 g in 1 TUBE April 29, 2025
46708-632-60 46708-632 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-632-60) / 60 g in 1 TUBE April 29, 2025
63629-2506-1 63629-2506 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2506-1) / 60 g in 1 TUBE May 18, 2021
63629-2507-1 63629-2507 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-2507-1) / 15 g in 1 TUBE May 18, 2021
72162-2005-2 72162-2005 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2005-2) / 15 g in 1 TUBE June 17, 2020
72162-2005-6 72162-2005 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2005-6) / 60 g in 1 TUBE June 17, 2020
0713-0661-15 0713-0661 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0661-15) / 15 g in 1 TUBE August 19, 2016
0713-0661-60 0713-0661 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0661-60) / 60 g in 1 TUBE August 19, 2016
51508-209-01 51508-209 Hubei Gedian Humanwell Pharmaceutical Co., Ltd. 1 kg in 1 CONTAINER, FLEXIBLE INTERMEDIATE BULK (51508-209-01) May 9, 2025
16714-729-01 16714-729 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-729-01) / 15 g in 1 TUBE June 1, 2017
16714-729-02 16714-729 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-729-02) / 60 g in 1 TUBE June 1, 2017
63187-747-15 63187-747 Proficient Rx LP 1 TUBE in 1 CARTON (63187-747-15) / 15 g in 1 TUBE October 3, 2016
63187-747-60 63187-747 Proficient Rx LP 1 TUBE in 1 CARTON (63187-747-60) / 60 g in 1 TUBE October 3, 2016
51672-1280-1 51672-1280 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1280-1) / 15 g in 1 TUBE June 30, 1992
51672-1280-3 51672-1280 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1280-3) / 60 g in 1 TUBE June 30, 1992
72578-086-01 72578-086 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-086-01) / 15 g in 1 TUBE June 17, 2020
72578-086-02 72578-086 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-086-02) / 60 g in 1 TUBE June 17, 2020
70771-1381-1 70771-1381 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1381-1) / 15 g in 1 TUBE November 25, 2019
70771-1381-3 70771-1381 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1381-3) / 60 g in 1 TUBE November 25, 2019
80425-0371 80425-0371 Advanced Rx of Tennessee, LLC — December 7, 2023
80425-0418 80425-0418 Advanced Rx of Tennessee, LLC — July 17, 2024
62332-632 62332-632 Alembic Pharmaceuticals Inc. — December 8, 2022
46708-632 46708-632 Alembic Pharmaceuticals Limited — April 29, 2025
63629-2506 63629-2506 Bryant Ranch Prepack — June 17, 2020
63629-2507 63629-2507 Bryant Ranch Prepack — June 17, 2020
72162-2005 72162-2005 Bryant Ranch Prepack — June 17, 2020
0713-0661 0713-0661 Cosette Pharmaceuticals, Inc. — August 19, 2016
51508-209 51508-209 Hubei Gedian Humanwell Pharmaceutical Co., Ltd. — May 9, 2025
16714-729 16714-729 NORTHSTAR RX LLC — June 30, 1992
63187-747 63187-747 Proficient Rx LP — August 1, 2013
51672-1280 51672-1280 Sun Pharmaceutical Industries, Inc. — June 30, 1992
72578-086 72578-086 Viona Pharmaceuticals Inc — June 17, 2020
70771-1381 70771-1381 Zydus Lifesciences Limited — November 25, 2019

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.